The cytochrome P-450 2C9/2C19 but not the ABCB1 genetic polymorphism may be associated with the liver cytochrome 3A4 induction by phenytoin

Journal of Clinical Psychopharmacology

Volumn 32, Issue 3, 2012, Pages 429-431

  Chhun, Stéphanie ^a   Verstuyft, Céline ^b   Rizzo Padoin, Nathalie ^c   Simoneau, Guy ^d   Becquemont, Laurent ^b   Bergmann, Jean François ^d   Mouly, Stéphane ^d  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b BICÊTRE HOSPITAL   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; MULTIDRUG RESISTANCE PROTEIN 1; PHENYTOIN;

ADULT; ALLELE; COMPUTER PROGRAM; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; EXON; GENE INTERACTION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; LETTER; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RASH;

ADULT; ALLELES; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; BREATH TESTS; CYTOCHROME P-450 CYP3A; ENZYME INDUCTION; ERYTHROMYCIN; FRANCE; GENE FREQUENCY; HUMANS; LIVER; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PHENYTOIN; POLYMORPHISM, GENETIC; RADIOACTIVE TRACERS; YOUNG ADULT;

EID: 84861045786     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182549c0c     Document Type: Letter

References (19)

1. Guengerich FP. Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol. 1999;39:1-17.
2. Paine MF, Hart HL, Ludington SS, et al. The human intestinal cytochrome P450 "pie". Drug Metab Dispos. 2006;34(5):880-886.
3. Backman JT, Olkkola KT, Ojala M, et al. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia. 1996;37(3):253-257.
4. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics. 1994;4(4): 171-184.
5. Hardman JG, Limbird LE, Molinoff PB, et al, eds. The Pharmacological Basis of Therapeutics. Goodman and Gilman's Edition. New York, NY: McGraw-Hill; 1996;591.
6. Bajpai M, Roskos LK, Shen DD, et al. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos. 1996;24(12):1401-1403.
7. Xie HG, Prasad HC, Kim RB, et al. CYP2C9 allelic variants: Ethnic distribution and functional significance. Adv Drug Deliv Rev. 2002;54(10): 1257-1270.
8. Mamiya K, Ieiri I, Shimamoto J et al. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia. 1998;39(12):1317-1323.
9. Kerb R, Aynacioglu AS, Brockmoller J, et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J. 2001;1(3):204-210.
10. Hoffmeyer S, Burk O, Von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97(7):3473-3478.
11. Chhun S, Verstuyft C, Rizzo-Padoin N, et al. Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers. Br J Clin Pharmacol. 2009;68(2):226-237.
12. Tate SK, Depondt C, Sisodiya SM, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A. 2005;102(15):5507-5512.
13. Donahue S, Flockhart DA, Abernethy DR. Ticlopidine inhibits phenytoin clearance. Clin Pharmacol Ther. 1999;66(6): 563-568.
14. Chaudhry AS, Urban TJ, Lamba JK, et al. CYP2C9*1B promoter polymorphisms, in linkage with CYP2C192, affect phenytoin autoinduction of clearance and maintenance dose. J Pharmacol Exp Ther. 2010;332(2):599-611.
15. Lamba J, Strom S, Venkataramanan R, et al. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther. 2006;79(4):325-338.
16. Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther. 2004; 75(1):13-33.
17. Ebid AH, Ahmed MM, Mohammed SA. Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: A gene polymorphism perspective study. Ther Drug Monit. 2007;29(3):305-312.
18. Simon C, Stieger B, Kullak-Ublick GA, et al. Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition. Acta Neurol Scand. 2007;115(4):232-242.
19. Zhang C, Kwan P, Zuo Z, et al. In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein. Life Sciences. 2010;86(23-24):899-905.